Voyager Token (CURRENCY:VGX) traded down 10.9% against the U.S. dollar during the 1 day period ending at 22:00 PM E.T. on August 17th. One Voyager Token coin can currently be purchased for about $3.62 or 0.00008028 BTC on cryptocurrency exchanges. During the last seven days, Voyager Token
Baker Tilly Wealth Management LLC lessened its holdings in Northrop Grumman Co. (NYSE:NOC) by 4.5% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,686 shares of the aerospace company's stock after selling 80 shares dur
Here's Advertisement
Asian digital products and services conglomerate Sea Limited (NYSE:SE) was a buoyant stock on Wednesday, closing more than 3% higher. The company benefited from a clutch of analyst upgrades, despite a mixed second quarter that featured a bottom-line miss.
So what
On the back of those earnings, which were published Tuesday, several prognosticators modified their expectations for Sea. And for the most part, they became more bullish.
Voyager Token (CURRENCY:VGX) traded down 10.9% against the U.S. dollar during the 1 day period ending at 22:00 PM E.T. on August 17th. One Voyager Token coin can currently be purchased for about $3.62 or 0.00008028 BTC on cryptocurrency exchanges. During the last seven days, Voyager Token
Baker Tilly Wealth Management LLC lessened its holdings in Northrop Grumman Co. (NYSE:NOC) by 4.5% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,686 shares of the aerospace company's stock after selling 80 shares dur
Imagine Uber, but with three times the drivers worldwide and 457 million more users - that's Didi Global Inc. (NYSE: DIDI).
And the Didi stock forecast for 2025 looks sunny, despite some short-term hiccups. Let's talk about why Didi could eventually dominate the global rideshare industry
Capital Asset Advisory Services LLC increased its holdings in Vanguard Mid-Cap ETF (NYSEARCA:VO) by 3,691.1% during the second quarter, HoldingsChannel reports. The fund owned 77,565 shares of the company's stock after acquiring an additional 75,519 shares during the quarter. Vanguard Mid-Cap
Forte Biosciences, Inc. (FBRX Quick QuoteFBRX ) announced that the mid-stage study of its lead product candidate FB-401, which is being evaluated for the treatment of atopic dermatitis, was not successful. Consequently, the company will not advance the study any further.
Shares o
Here's Advertisement